Manish Kumar

Dr. Manish Kumar


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HYHayrettin Yavuz
Hayrettin Yavuz
MKManish Kumar
Manish Kumar
HGHimanshu Ballav Goswami
Himanshu Ballav Goswami
UEUta Erdbrügger
Uta Erdbrügger
WHWilliam T. Harris
William T. Harris
ASAgnieszka Swiatecka-Urban
Agnieszka Swiatecka-Urban
As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a significant comorbidity that is increasingly linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes, yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary extracellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease management in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.

24 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
HYHayrettin Yavuz
Hayrettin Yavuz
MKManish Kumar
Manish Kumar
HGHimanshu Ballav Goswami
Himanshu Ballav Goswami
UEUta Erdbrügger
Uta Erdbrügger
WHWilliam T. Harris
William T. Harris
ASAgnieszka Swiatecka-Urban
Agnieszka Swiatecka-Urban
As people with cystic fibrosis (PwCF) live longer, kidney disease is emerging as a sig-nificant comorbidity that increasingly is linked to cardiovascular complications and progression to end-stage kidney disease. In our recent review, we proposed the unifying term CF-related kidney disease (CFKD) to encompass the spectrum of kidney dysfunction observed in this population. Early detection of kidney injury is critical for improving long-term outcomes yet remains challenging due to the limited sensitivity of conventional laboratory tests, particularly in individuals with altered muscle mass and unique CF pathophysiology. Emerging approaches, including novel blood and urinary biomarkers, urinary ex-tra-cellular vesicles, and genetic risk profiling, offer promising avenues for identifying subclinical kidney damage. When integrated with machine learning algorithms, these tools may enable the development of personalized risk stratification models and targeted therapeutic strategies. This precision medicine approach has the potential to transform kidney disease man-agement in PwCF, shifting care from reactive treatment of late-stage disease to proactive monitoring and early intervention.